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Introduction
Transdermal delivery of  drugs through the skin to the systemic 
circulation provides convenient route of  administration for a va-
riety of  clinical indications. For transdermal delivery of  drugs, 
stratum corneum is the main barrier layer for permeation of  
drug. Hence to increase the flux through skin membrane, differ-
ent approaches of  penetration enhancement are used [Hemant 
etal., 2012]. The main aim of  novel drug delivery is to maintain 
the constant and effective drug level in the body with simulta-
neous minimization of  side effects. Novel drug delivery system 
also localizes the drug action by placing control release system 
adjacent to diseased tissue or organ; or target the drug delivery 
by using drug carriers. At present, not a single drug delivery sys-
tem fulfills all the criteria but, attempts have been made through 
novel approaches. Today, numbers of  novel approaches have 
emerged covering various routes of  administration, to achieve ei-
ther controlled or targeted delivery. Vesicular drug delivery is one 
of  the approaches which encapsulates the drug eg. Liposomes, 
niosomes, transferosomes, pharmacosomes, and provesicles like 
proliposomes and proniosomes. [Pradnya etal., 2012].
Proniosomes are dry formulations of  water-soluble carrier par-
ticles that are coated with surfactant and hydrated by agitation 
in hot water for a short period of  time, offer a versatile vesicle 
delivery concept with the potential for drug delivery via the trans-
dermal route . This would be possible if  proniosomes form ni-
osomes following topical application under occlusive conditions, 
due to hydration by water from the skin itself. The aim of  this 
study is to investigate the feasibility of  using proniosomes as a 
transdermal drug delivery system for Candesartan Cilexetil [Ibra-
him etal., 2005]. Vesicles prepared were characterized by optical, 
scanning and transmission microscopy for vesicle formation and 
morphology. Drug encapsulation efficiency and release studies 
were carried out. Finally, a stability study of  proniosomal formu-
lations was also performed to investigate the leaking of  the drug 
during storage [ Rishu etal., 2011].
Materials And Methods
Candesartan Cilexetil was obtained as a gift sample from Ran-
baxy Research & Development Centre, Gurgaon, India, Span 
20, 40, 60, 65 & 80 was procured from Central Drug House, 
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Mumbai, Cholesterol A. R. was purchased from Central Drug 
House, Mumbai. Lecithin was also obtained from Central Drug 
House, Mumbai. Isopropyl alcohol (Thomas Baker (Chemicals), 
Mumbai), potassium dihydrogen orthophosphate (Central Drug 
House), sodium hydroxide pellets (E-Merck) and other chemi-
cals were of  analytical reagent grade. Distilled water was used 
throughout the study.
Preparation of  Proniosomes
Candesartan Cilexetil proniosomes were prepared by coacerva-
tion phase separation method. Precisely weighed amounts of  
surfactant, lecithin, cholesterol and drug were taken in a clean 
and dry wide mouthed glass vial of  5.0 ml capacity and alcohol 
(0.5 ml) was added to it. After warming, all the ingredients were 
mixed well with a glass rod. The open end of  the glass bottle 
was covered with a lid to prevent the loss of  solvent from it 
and warmed over water bath at 60-70°C for about 5 min until 
the surfactant mixture was dissolved completely. Then the aque-
ous phase (0.1% glycerol solution) was added and warmed on a 
water bath till a clear solution was formed which was converted 
into proniosomal gel on cooling . [Sanskar etal 2010] (Table 1). 
                                                                                       
                                         
Evaluation of   Proniosomes
pH Determination
The pH of  each Proniosomal gel was determined using pH 
meter (Model GMPH, Labindia, Mumbai.). The electrode first 
calibrated with pH 4.0 and pH 7.0 solution then readings were 
recorded on pH meter for each formulation (AH1 to AH4). [He-
mant etal., 2012] 
Viscosity Determination 
Viscosities of  the formulated Proniosomal gels were determined 
using Brookfield Viscometer (DV-II + Pro) with T-Shaped spin-
dle set using Spindle no.92 at 2 rpm at 25°C. [Sudhamani etal., 
2010]
Formulation
Code
Surfactant
Type
Ratio 
(mg)
Drug 
(mg)
Lecithin
(mg)
Cholesterol
(mg)
Alcohol
(ml)
Glycerol
Solution 
(ml)
AH1 S20:S40 500:500 10 100 100 0.5 0.18
AH2 S20:S60 500:500 10 100 100 0.5 0.18
AH3 S20:S80 500:500 10 100 100 0.5 0.18
AH4 S40:S80 500:500 10 100 100 0.5 0.18
Optical Microscopy
A drop of  niosomal dispersion prepared from proniosomes was 
spread on a glass slide and examined for the vesicle structure and 
presence of  insoluble drug crystals under the light microscope 
with varied magnification power. Photomicrographs were taken 
for niosomes using a digital camera with 6X optical 200 m. The 
proniosomal gel (100 mg) was hydrated with Phosphate buffer 
pH 7.4  (10 ml) in a small test tube by manual shaking for 5 min 
and the resulting niosomes were observed under optical micro-
scope at 100 X magnification.[ Shamsheer etal., 2011]
Entrapment Efficiency
Percent encapsulation efficiency (EE) as determines by centrifu-
gal method. The proniosomal gel was converted to niosomal dis-
persion, which as centrifuged (18000 rpm) for 40 min at 5ºC in 
order to separate unentrapped drug. The supernatant as taken and 
diluted with phosphate buffer pH 7.4. The drug concentration is 
the resulting solution was assayed spectrophotometrically at 257 
nm. The percentage of  drug encapsulation was calculated by the 
equation .
                         EE (%) = [(Ct - Cf)/ Ct] × 100
                                                 
Where Ct is the concentration of  total drug and Cf  is the concen-
tration of  unentrapped drug.[Chandra etal., 2008]
Particle size analysis
The mean particle size and the polydispersity index (PI) were de-
termined by Malvern Mastersizer (Malvern Instruments Ltd, Mal-
vern, UK). Prior to the measurement, the samples were diluted 
with double distilled water to suitable scattering intensity and re-
dispersed by handshaking. [Abdallah etal., 2011]
Scanning electron microscopy (SEM)
The size and shape of  hydrated niosomal dispersion prepared 
from proniosomes were also determined by SEM. Prior to analy-
sis; the samples were diluted with ultra purified water to obtain 
a suitable concentration. Then, the samples were spread on a 
sample holder (stub) and dried using vacuum. They were subse-
quently subjected to gold palladium coating (JFC 1200 fine coat-
er, JEOL, Japan) and examined by scanning electron microscope 
(JSM 6301F, JEOL, Japan). SEM, micrograph clearly shows the 
niosomes of  different formulation on the basis of  production pa-
rameter. [Aqil etal., 2004]
Transmission electron microscopy (TEM)
The morphology of  hydrated niosomal dispersion prepared from 
proniosome as also determined by transmission electron micros-
copy. A drop of  niosomal dispersion was applied to a carbon – 
coated 300- mesh copper grid and left to adhere on the carbon 
Table1: Composition of  proniosomal formulations prepared
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substrate for about 1 min. The remaining dispersion was re-
moved by a piece of  filter paper. A drop of  2 % aqueous solution 
of  uranyl acetate as applied for 35 seconds and again the solution 
in excess was removed by the tip of  filter paper. The sample was 
air dried and observed under the transmission electron micro-
scope at 90 KV. [Mahmoud etal., 2008]
In vitro release study
In vitro release studies on proniosomal gel were performed us-
ing locally manufactured Franz-diffusion cell. The area of  donor 
compartment exposed to receptor compartment was 1.41cm2. 
The dialysis cellophane membrane (MMCO14KDC) was mount-
ed between the donor and receptor compartment. A one gram 
of  proniosomal gel was placed on one side of  the dialysis mem-
brane. The receptor medium was containing 200ml solution of  
isopropyl alcohol and isotonic phosphate buffer of  pH 7.4 in the 
ratio of  20:80. The receptor compartment was surrounded by a 
water jacket to maintain the temperature at 37±1oC. Heat was 
provided using a thermostatic hot plate with a magnetic stirrer. 
The receptor fluid was stirred by a Teflon-coated magnetic bead 
fitted to a magnetic stirrer. At each sampling interval, samples 
were withdrawn and were replaced by equal volumes of  fresh re-
ceptor fluid on each occasion. Samples withdrawn were analyzed 
spectrophotometrically (Shimadzu-1700) at 257 nm. [Chetna 
etal., 2011, Narayan etal., 2011]
 
Ex- vivo  skin permeation studies
Permeation of  Candesartan Cilexetil, through excised rat skin, 
from the optimized proniosomal preparation was assessed. The 
abdominal hair of  male wistar rats `( 150 ± 50 gm) was removed 
carefully. After the animal were sacrificed, the abdominal skin 
was excised and the adhering fat eliminated. The whole skin was 
equilibrated in phosphate buffer solution (pH 7.4, the human 
blood pH) for 1 h before the experiment. [Agaiah etal., 2012] 
This membrane was mounted on a vertical franz type diffusion 
cell with the dermis facing the receptor compartment. The donor 
side was charged with 200 mg of  the investigated Preparation. 
The membrane surface area available for diffusion was 3.14cm2. 
The receptor compartment was filled with buffer, temperature 
was maintained at 37 ± 0.5oC to simulate human blood tempera-
ture. The receptor compartment was constantly stirred at 300 
rpm. Sample from the receptor fluid (2ml) were withdrawn at 
various time intervals upto 24 h and replace immediately by fresh 
buffer solution; to maintain the “ sink” conditions constantly and 
a constant volume as well. The samples were then assayed  spec-
trophotometrically at 257 nm.[ Rita etal., 2012]
Skin irritation study 
The albino Wistar rats were housed in polypropylene cages, with 
free access to standard laboratory diet and water. Animals were 
acclimatized for at least 7 days before experimentation. The dor-
sal abdominal skin of  rats was shaved 24 h before study. Trans-
dermal gel was applied and site of  application was occluded with 
gauze and covered with a nonsensitizing microporous tapes. For-
malin (0.8 %w/v) solution was applied as standard skin irritant. 
The formulation was removed after 24 h and score of  erythema 
was recorded and was compared with standard.[ Raja etal., 2011]
Stability study 
Stability studies were carried out by storing the optimized for-
mulation (AH2) at various temperature conditions as per ICH 
guidelines i.e. at refrigeration temperature (2°-8°C), room tem-
perature (25°± 0.5°C) for a period of  two months. Entrapment 
Efficiency and variation in the average vesicle diameter were de-
termined before and after the completion of  2 months.[ Kan-
dasamy etal., 2010]
Statistical analysis
All data are reported as mean ± standard error of  mean and the 
differences between the groups were tested using Student’s t-test 
at a significance level of  P< 0.05. More than two groups were 
compared using analysis of  variance and the difference of  P< 
0.05 was considered significant.
Results And Discussion
pH Determination.
Skin compatibility is the primary requirement for a good topical 
formulation, it was found that the pH of  all the formulations 
were in the range of  5.24 to 7.40 that suits the skin pH, indicating 
skin compatibility. The results of  pH determination are reported 
in Table 2.
Viscosity Determination.
Viscosity measurement of  all the formulations revealed opti-
mum consistency and the results are reported in Table 3
      S.No. Formulation 
Code
Viscosity  
(centipoises)
1 AH1 46115 ± 1.11
2 AH2 47889  ±  1.13
3 AH3 45223±   0.92
4 AH4 43667±  0.34
Entrapment Efficiency.
The EE of  all proniosomal formulations are reported in Table 
4. Candesartan Cilexetil was best encapsulated by proniosomal 
prepared using Span 20 : Span60 (AH2). This might be attributed 
to the fact that Spans 60 and 40 are solid at room temperature 
and showed a higher phase transition temperatures [Tc]. It was 
found from the result that the entrapment efficiency of  Span 
80 formulations was less than those of  Span 60 formulations as
S.No. Formulation 
Code
pH
1 AH1 5.24 ±0.05
2 AH2 6.23 ±0.6
3 AH3 6.98±0.12
4 AH4 7.40±0.02
 Table 2: pH of  proniosome gel formulation
Table 3: Viscosity of proniosome gel formulation
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  Spans 60 and 80 have the same head group, but Span 80 has an 
unsaturated alkyl chain. Introduction of  a double bond into the 
paraffin chain causes a marked enhancement in the permeability 
in liposomes. This might be the reason for the lower entrapment 
efficiency of  the Span 80 system.
Optical Microscopy.
The photomicrographs of  hydrated AH2 optimized proniosomal 
formulations, composed of   Span 20 : Span60  respectively.
The prepared vesicles were studied under 400x magnifications 
to observe the formation of  vesicles. Some unevenness of  vesi-
cles that observed under the study may be due to drying process 
under normal environment condition. The photographs revealed 
that the niosomes are unilamellar vesicles having spherical shape 
and no aggregation or agglomeration  is observed. 
Particle size analysis.
The particle size and polydispersity index (PDI) were determined 
by Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK). 
The particles exhibit Brownian motion, which causes the inten-
sity of  light to scatter from particles, which is then detected as a
change in intensity with suitable optics and a photo multiplier. 
All the data analyses were performed in automatic mode with 
triplicate measurement within each run. Mean Average particle 
size of  formulations AH1, AH2, AH3 and AH4 were found to 
be 277.8, 227.5, 203.1 and 175.6 respectively. Polydispersity index 
of  these formulations were found to be 0.900, 0.270, 0.311 and 
0.303 respectively in Table 5.
Determination of  particle size is an important parameter for the 
topical application. Size was reduced when the dispersion was 
agitated. The reason for this is the energy applied in the agita-
tion which results in the breakage of  the larger vesicles to smaller 
vesicles. The size range was found to be 175.6-277.8 nm. Particle 
size of  optimized AH2 formulation was found to be 227.5nm. 
Particle size was found to be smallest in AH4 formulation (175.6 
nm) due to the presence of  Span 80. Increasing hydrophobicity 
of  the surfactant monomer led to a smaller vesicle, a result that 
is expected since surface energy decreases with increasing hydro-
phobicity.
Scanning Electron Microscopy (SEM).
Figure 2: Scanning electron image of  hydrated AH2 proni-
osomal formulation (at 25 kV with magnification 2,000 X)
Surface morphology confirms the coating of  surfactant in carrier. 
Results of  scanning electron microscopic study of  niosomes pre-
pared from AH2 proniosomal formulations shows the vesicles 
are well identified, spherical and discreet with sharp boundaries 
having large internal aqueous space.
Transmission Electron Microscopy (TEM).
Figure 3: Transmission electron micrograph of  hydrated 
AH2 proniosomal formulation (at 90 kV with magnification 
100,000X)
Results of  transmission electron microscopic study of  niosomes 
prepared from AH2 proniosomal formulations shows the vesi-
cles are well identified, spherical and discreet with sharp bounda-
ries having large internal aqueous space.
S.No. Formula-
tion Code
Entrapment  
Efficiency*  ± SD
1 AH1 73.76  ± 1.51
2 AH2 78.71 ± 1.48
3 AH3 64.78 ± 1.72
4 AH4 63.18± 1.63
 Table 4:  Entrapment Efficiency of  hydrated  
Proniosomes
S.No Formula-
tion code
Particle 
size(d.nm)
Polydispersity 
Index (PdI)
1 AH1 277.8 0.9
2 AH2 227.5 0.27
3 AH3 203.1 0.031
4 AH4 175.6 0.303
Table 5:  Particle size determination of  proniosome gel 
formulation
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In vitro release study.
The release of  Candesartan Cilexetil from the investigated stable 
formulation follows zero order kinetics with an immediate release 
of  Candesartan Cilexetil (no lag time). Comparing the release pro-
file of  other formulation it was found that the formulation which 
have increasing hydrophobicity shows better release. Results are 
shown in Figure. 4.
Ex- vivo  skin permeation studies.
Figure 5 shows that permeation of  Candesartan Cilexetil en-
trapped in proniosomal optimized formulation through the skin 
follows zero order kinetics. It is also evident that the optimized 
formulation effectively enhanced Candesartan Cilexetil permea-
tion, showing higher flux value. In order to verify the predominant 
driving force for Candesartan Cilexetil proniosomes permeating 
across skin, some efforts were made to clarify these mechanisms. 
The release rate of  the drug across cellophane membrane was 
previously determined and compared to its flux through rat skin.
Skin irritation study 
No erythema was found after 7 days when optimized formulation 
AH2 was applied to the dorsal skin of  rat and compared with 
standard irritant. Thus the formulation was found to be suitable 
for transdermal application. 
Stability study 
From the results of  vesicular size and shape and entrapment effi-
ciency of  the optimized formulation (AH2) it was concluded that 
the formulation was stable at refrigeration and room temperature 
as well (Table 6)
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Figure 4: Release profile of  Proniosomal gel of  Candesartan Cilexetil
Figure 5: Permeation profile of  Proniosomal gel of  Candesartan cilexetil
S. No Temp Initial After two month
EE Vesicle 
size 
(nm)
EE Ves-
icle 
size
(nm)
1 2ºC 78.71±1.48 497.2 78.50±1.23 500.1
2 25ºC 78.71±1.48 497.2 78.53±1.56 502.4
Table 6:  Results of stability studies of optimized 
formulation (AH2)
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Conclusion
The Transdermal Proniosomal Gels showed controlled drug re-
lease properties. The results of  the present study indicated that 
Candesartan Cilexetil proniosomal gel containing lecithin, choles-
terol and in combination of  surfactants like span 20, 40, 60, 80 
shows sustained release of  drug over a period of  24 hrs for the 
management of   hypertension. The optimized AH2 proniosomal 
gel system showed better in-vitro and ex-vivo permeation study 
and will be a great potential for delivery of  anti hypertensive drug 
Candesartan Cilexetil. Thus proniosomal gel could be an effec-
tive alternative vehicle for delivering the drug through transder-
mal route to avoid side effects associated with oral route. Thus 
Proniosomes may be a promising carrier for Candesartan Cilexetil 
and other drugs, especially due to their simple production and fac-
ile scale up. However, benefit-to-risk ratio and clinical intricacies 
need to be estab¬lished scientifically through in vivo studies, for 
its suitability in clinical practice in the monitoring of  antihyper-
tensive activity of  the prepared proniosomal gel through topical 
route. Thus, in conclusion, proniosomal formulation of  Cande-
sartan Cilexetil holds an immense potential for the development 
of  topical antihypertensive agent comparable to conventional oral 
antihypertensive agent.
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